Amneal Pharmaceuticals is a diversified biopharmaceutical company that develops, manufactures, and distributes essential medicines globally through three main business segments. The Affordable Medicines segment produces over 280 generic and biosimilar product families, including complex formulations such as injectables, respiratory products, and biosimilars for oncology and specialty indications, with a focus on first-to-file and first-to-market opportunities that command stronger margins and longer market life. The Specialty segment markets branded proprietary pharmaceuticals targeting central nervous system and endocrine disorders, with revenue concentrated during periods of market exclusivity before generic competition erodes sales. The AvKARE segment operates as a pharmaceutical distributor primarily serving the U.S. government and institutions serving low-income populations. The company generates revenue through generic and branded pharmaceutical sales at variable margins, biosimilar commercialization, and strategic partnerships involving manufacturing, licensing, and supply agreements with tiered royalties and profit-sharing arrangements.